TITLE

The Oxford Participation and Activities Questionnaire: study protocol

AUTHOR(S)
Morley, David; Dummett, Sarah; Kelly, Laura; Dawson, Jill; Fitzpatrick, Ray; Jenkinson, Crispin
PUB. DATE
January 2014
SOURCE
Patient Related Outcome Measures;2014, Vol. 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: With an ageing population and increasing demands on health and social care services, there is growing importance attached to the management of long-term conditions, including maximizing the cost-effectiveness of treatments. In line with this, there is increasing emphasis on the need to keep people both active and participating in daily life. Consequently, it is essential that well developed and validated instruments that can meaningfully assess levels of participation and activity are widely available. Current measures, however, are largely focused on disability and rehabilitation, and there is no measure of activity or participation for generic use that fully meets the standards set by regulatory bodies such as the US Food and Drug Administration. Here we detail a protocol for the development and validation of a new patient-reported outcome measure (PROM) for assessment of participation and activity in people experiencing a variety of health conditions, ie, the Oxford Participation and Activities Questionnaire (Ox-PAQ). The stages incorporated in its development are entirely in line with current regulations and represent best practice in the development of PROMs. Methods: Development of the Ox-PAQ is theoretically grounded in the World Health Organization International Classification of Functioning, Disability, and Health. The project incorporates a new strategy of engaging with stakeholders from the outset in an attempt to identify those characteristics of PROMs considered most important to a range of potential users. Items will be generated through interviews with patients from a range of conditions. Pretesting of the instrument will be via cognitive interviews and focus groups. A postal survey will be conducted, with data subject to factor and Rasch analysis in order to identify appropriate dimensions and redundant items. Reliability will be assessed by Cronbach's alpha and item-total correlations. A second, large-scale postal survey will follow, with the Ox-PAQ being administered in conjunction with generic measures of health status to further test the validity of the measure. The Ox-PAQ will again be administered at 2 weeks to assess test-retest reliability and at 3 months to assess responsiveness. Conclusion: The development of the Ox-PAQ is a timely one. With increasing emphasis being placed on the importance of keeping people active and participating in daily life, the instrument has the potential for significant uptake. Its primary use is intended to be in clinical trials and for evaluation of interventions targeted at maintaining activity and participation.
ACCESSION #
94752416

 

Related Articles

  • McClellan moves on, sets sights on drug reimbursement. Bouchie, Aaron // Nature Biotechnology;Apr2004, Vol. 22 Issue 4, p366 

    Reports on the confirmation by the US senate of Mark McClellan as the administrator for the Centers for Medicare and Medicaid Services (CMS; Baltimore, MD, USA). Details of the last position at the Food and Drug Administration (FDA; Rockville, MD, USA) held by McClellan; Reason for the CMS to...

  • Get set for new MedWatch forms.  // Drug Topics;3/8/2004, Vol. 148 Issue 5, p7 

    Presents information regarding the U.S. Food and Drug Administration's revised MedWatch Voluntary Reporting Form and revised Mandatory Reporting Form. Questions related to single-use devices that are included in the form; Period wherein reporters can still have the option to use the existing...

  • Validation Failure is Not an Option. Should it Be? Krause, Stephen // BioPharm International;Jun2008, Vol. 21 Issue 6, p82 

    The author comments on the failure of the U.S. Food and Drug Administration's Q9 guidelines on risk management, to set clear expectations for how to set risk-based acceptance criteria in validation protocols and for not including instructions on how to deal with validation failures. He points...

  • Pressure Grows to Publish Data. Ward, Philip // Applied Clinical Trials;Nov2010, Vol. 19 Issue 11, p18 

    The article reports on the existing regulations concerning the publication of clinical trial results in the U.S. It states that the implementation of data measures should include trials of drug and non-drug interventions to enable better decision making in healthcare. It notes that the...

  • When I use a word … Innovations—‘The Births of Time’. Aronson, Jeffrey K. // QJM: An International Journal of Medicine;Oct2012, Vol. 105 Issue 10, p1037 

    No abstract available.

  • Move for more Medicare off-label cancer drugs creates contention.  // Reactions Weekly;2/28/2009, Issue 1241, p1 

    This article reports on the move made by Medicare to increase its coverage of off-label cancer therapies in the U.S. This move has reignited the debate over the safety and cost-effectiveness of therapies not approved by the U.S. Food and Drug Administration. According to supporters of the move,...

  • New FDA app guidelines.  // Contemporary OB/GYN;Oct2013, Vol. 58 Issue 10, p16 

    The article reports on the move by the U.S. Food and Drug Administration (FDA) on September 23, 2013 to issue a final guidance on mobile applications (app), claiming that it would only control specific medical apps.

  • A sterile applicator for a non-sterile solution: Making sense of new FDA requirements. Morrison, Allan J. // Healthcare Purchasing News;Aug2015, Vol. 39 Issue 8, p29 

    The article offers information on the ChloraPrep line of topical antiseptics from medical technology corporation CareFusion.

  • FMOLHS and Cook Medical take a standards road trip. Conway, Karen // Healthcare Purchasing News;Nov2015, Vol. 39 Issue 11, p66 

    The article presents information on the standardization of the supply chain and customer service processes of Cook Medical and Franciscan Missionaries of Our Lady Health System (FMOLHS). Topics include the concept of Global Trade Item Numbers (GTINs), the unique device identification (UDI) rule...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics